Beta Bionics develops the iLet Bionic Pancreas, an insulin delivery system that autonomously calculates and administers insulin doses based on real-time data from continuous glucose monitors. This technology eliminates the need for manual carb counting and insulin dose adjustments, providing a streamlined solution for diabetes management.

Encoded develops a genetic‑medicine platform that uses precise cellular targeting and advanced gene‑regulation techniques to create one‑time gene therapies for neurological disorders. By identifying unique genetic signatures of disease‑relevant cells, the platform delivers therapeutic payloads with high specificity, improving potency and reducing off‑target effects for both monogenic and broader neurodegenerative conditions.

Rocket Pharmaceuticals develops curative gene‑therapy treatments for rare, devastating genetic diseases by leveraging a dual platform strategy—ex vivo lentiviral vectors for hematopoietic targets and in vivo adeno‑associated viral vectors for systemic delivery. Their pipeline focuses on high‑unmet‑need bone‑marrow‑derived and cardiovascular disorders, selecting the optimal technology for each indication to deliver durable, disease‑modifying outcomes.